1-3 of 3
Joycelynne Palmer, Ph.D
Close
Sort by
Journal Articles

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

Auayporn Nademanee, MD, Andrew Raubitschek, MD, Arturo Molina, MD, Joycelynne Palmer, Ph.D, Ni-Chun Tsai, MS, Amrita Krishnan, MD, Neil Kogut, MD, Stephen Forman, MD
Journal: Blood
Blood (2007) 110 (11): 1891.
https://doi.org/10.1182/blood.V110.11.1891.1891
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

Auayporn P. Nademanee, MD, Amrita Krishnan, M.D, Nicole Tsai, MS, MPH, Joycelynne Palmer, Ph.D., Arturo Molina, M.D., Henry C. Fung, M.D., David Yamauchi, M.D, Neil Martin Kogut, M.D., Stephen J. Forman, M.D., Andrew Raubitschek, M.D.
Journal: Blood
Blood (2006) 108 (11): 327.
https://doi.org/10.1182/blood.V108.11.327.327
Published: 2006
Journal Articles

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Auayporn P. Nademanee, MD, Jasmine M. Zain, M.D., Joycelynne Palmer, Ph.D., Nicole Tsai, M.S., M.P.H., Neil Martin Kogut, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Roberto Rodriguez, M.D., Eileen Patricia Smith, M.D., Stephen J. Forman, M.D.
Journal: Blood
Blood (2006) 108 (11): 3060.
https://doi.org/10.1182/blood.V108.11.3060.3060
Published: 2006